About: Elucidation of the mechanism of anti-herpes action of two novel semisynthetic cardenolide derivatives

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Elucidation of the mechanism of anti-herpes action of two novel semisynthetic cardenolide derivatives Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Elucidation of the mechanism of anti-herpes action of two novel semisynthetic cardenolide derivatives
Creator	Alves, José Boff, Laurita Braga, Castro Cláudia, · Fernanda, Naira Fernão, · Flaviano, · Gabriela, · Kreis, Wolfgang Maia De Pádua, Rodrigo Munkert, Jennifer Ottoni, Melo Ramos, Silva Ricardo, · Schneider, Zanchett Simões, Maria
source	Medline; PMC
abstract	Human herpesviruses are among the most prevalent pathogens worldwide and have become an important public health issue. Recurrent infections and the emergence of resistant viral strains reinforce the need of searching new drugs to treat herpes virus infections. Cardiac glycosides are used clinically to treat cardiovascular disturbances, such as congestive heart failure and atrial arrhythmias. In recent years, they have sparked new interest in their potential anti-herpes action. It has been previously reported by our research group that two new semisynthetic cardenolides, namely C10 (3β-[(N-(2-hydroxyethyl)aminoacetyl]amino-3-deoxydigitoxigenin) and C11 (3β-(hydroxyacetyl)amino-3-deoxydigitoxigenin), exhibited potential anti-HSV-1 and anti-HSV-2 with selectivity index values > 1,000, comparable with those of acyclovir. This work reports the mechanism investigation of anti-herpes action of these derivatives. The results demonstrated that C10 and C11 interfere with the intermediate and final steps of HSV replication, but not with the early stages, since they completely abolished the expression of the UL42 (β) and gD (γ) proteins and partially reduced that of ICP27 (α). Additionally, they were not virucidal and had no prophylactic effects. Both compounds inhibited HSV replication at nanomolar concentrations, but cardenolide C10 was more active than C11 and can be considered as an anti-herpes drug candidate including against acyclovir-resistant HSV-1 strains.
has issue date	2020-04-29(xsd:dateTime)
bibo:doi	10.1007/s00705-020-04562-1
bibo:pmid	32346764
has license	no-cc
sha1sum (hex)	63a9f00737727183b0af12eece75fad64e9d0899
schema:url	https://doi.org/10.1007/s00705-020-04562-1
resource representing a document's title	Elucidation of the mechanism of anti-herpes action of two novel semisynthetic cardenolide derivatives
has PubMed Central identifier	PMC7188521
has PubMed identifier	32346764
schema:publication	Arch Virol
resource representing a document's body	covid:63a9f00737727183b0af12eece75fad64e9d0899#body_text
is schema:about of	named entity 'This' named entity 'virus' named entity 'Both' named entity 'semisynthetic' named entity 'HERPESVIRUSES' named entity 'HSV-1' named entity 'ACYCLOVIR' named entity 'PATHOGENS' named entity 'prophylactic' named entity 'replication' named entity 'intermediate' named entity 'HSV-1' named entity 'potential' named entity 'reduced' named entity 'virucidal' named entity 'completely' named entity 'cardenolide' named entity 'comparable' named entity 'arrhythmias' named entity 'C10' named entity 'C11' named entity 'drug candidate' named entity 'cardenolides' named entity 'acyclovir' named entity 'herpes' named entity 'semisynthetic' named entity 'congestive heart failure' named entity 'herpes' named entity 'herpes' named entity 'C11' named entity 'Elucidation' named entity 'hydroxyethyl' named entity 'viruses' named entity 'nucleoside analogs' named entity 'C11' named entity 'Western blot' named entity 'Göteborg' named entity 'Dassel' named entity 'viruses' named entity 'sugar' named entity 'C10' named entity 'C10' named entity 'Cardenolides' named entity 'internal control' named entity 'potency' named entity 'viral replication cycle' named entity 'ACV' named entity 'intercellular propagation' named entity 'C11' named entity 'supernatants' named entity 'HSV-1' named entity 'Sigma-Aldrich' named entity 'intracellular' named entity 'Sweden' named entity 'HSV-2' named entity 'HSV' named entity 'DNA viruses' named entity 'late proteins' named entity 'HSV-1' named entity 'cytotoxic' named entity 'C11' named entity 'herpesvirus' named entity 'digitoxin' named entity 'pathologies' named entity 'HSV' named entity 'ACV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software